Stockscreener 앱 받기
29.97
0.43%
-0.13
시장 영업 전:
29.46
-0.51
-1.70%
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Nasdaq
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com
Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA
Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN
An Overview of Agios Pharmaceuticals's Earnings - Nasdaq
Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times
Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
New Strong Sell Stocks for April 3rd - TradingView
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India
Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
0.39%
3.66%
자본화:
|
볼륨(24시간):